Jan 07, 2023 / 05:00AM GMT
Unidentified Company Representative -
Hello, everyone. Now we'd like to start Eisai's conference for media and investors. Thank you very much for joining today out of your very busy schedule at the beginning of the new year in spite of the short notice. Today, Japan time and on January 6 U.S. time, treatment for AD, lecanemab, or LEQEMBI as its U.S. brand name was granted accelerated approval for U.S. FDA.
This morning at 4:30 a.m. JST, we issued a press release related to the accelerated approval and the statement on our U.S. pricing and the rationale behind, and LEQEMBI safety statement from the Global Safety Officer.
At 1:30 p.m., we filed a partial change application from the accelerated approval to full traditional approval. In this conference today, we'd like to explain our thinking behind the pricing for LEQEMBI. Today's conference is organized, both on-site and online in a hybrid fashion. We thank on-site participants for wearing their face mask to prevent COVID-19 infections. Those joining on site can find in your handout 4 takes of documents, including a release and statements and the
Eisai Co Ltd Approach to US Pricing for LEQEMBI Briefing Transcript
Jan 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers